🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07827183
Recruiting Not applicable

AI-Personalized Discharge Education for Patients After Lung Cancer Surgery

NCT07827183 · tracked via the Priya Life Science China tracker
Sponsor
Xiamen University
Phase
Not applicable
Started
2026-08-15
Last updated
2026-09-18

Condition(s) studied

Lung Cancer (Diagnosis)

Investigational drug(s) / intervention(s)

AI-Personalized Discharge EducationRoutine Discharge Education

AI-Personalized Discharge Education: Participants receive an individualized discharge guidance plan generated by an artificial intelligence system based on clinical and care-related information, including surgical approach, extent of lung resection, pain and dyspnea scores, comorbidities, discharge medications, home care conditions, educational level, smoking history, and postoperative complications. The guidance includes medication instructions, respiratory exercises, wound and activity management, follow-up planning, and warning signs requiring medical attention. All AI-generated content is reviewed by a responsible nurse before being provided to the participant or caregiver.

Routine Discharge Education: Participants receive routine discharge education provided by nursing staff, including verbal instructions and a standardized printed discharge booklet covering medication use, wound care, respiratory exercises, physical activity, diet, follow-up, and other routine postoperative care.

Study summary

This randomized controlled trial evaluates the effect of artificial intelligence (AI)-personalized discharge education on discharge teaching quality and recovery outcomes in patients after lung cancer surgery. Eligible participants will be randomly assigned in a 1:1 ratio to either an intervention group or a control group. The control group will receive routine discharge education, including verbal instructions and a standardized printed discharge booklet. The intervention group will receive the same routine education plus an AI-generated personalized discharge guidance plan based on individual clinical and care-related information. All AI-generated content will be reviewed by a responsible nurse before being provided to participants. The primary outcome is the quality of discharge teaching measured on the day of discharge. Secondary outcomes include self-efficacy for postoperative rehabilitation management and quality of life assessed one month after discharge.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Pathologically confirmed primary lung cancer and underwent radical lung cancer surgery by thoracoscopic or open approach, including lobectomy, pneumonectomy, or wedge resection. 2. Age 18 to 80 years. 3. Clinical stage I to III. 4. No distant organ metastasis. 5. Clinically stable after surgery, conscious, and able to perform basic listening, speaking, and reading activities, with planned discharge to home for recovery. 6. The participant or primary caregiver is able to use a smartphone and WeChat. 7. Able and willing to provide informed consent and voluntarily participate in the study. Exclusion Criteria: 1. Recurrent lung cancer or previous treatment with targeted therapy, chemotherapy, or radiotherapy. 2. Severe aphasia, cognitive impairment (MMSE \<24), or psychiatric disorders that prevent independent completion of study questionnaires. 3. Severe cardiac, hepatic, or renal dysfunction, or another malignant tumor. 4. Severe postoperative complications requiring prolonged hospitalization, such as bronchopleural fistula or major bleeding. 5. Participation in another interventional clinical study. 6. Unable to complete the 1-month follow-up because of travel or residence outside the study area after discharge.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Siping Central People's Hospital Siping Jilin Recruiting

More Xiamen University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07827183 on ClinicalTrials.gov ↗ ← All trials in China